Please click here for a quick reference guide providing an overview of key elements of FDA’s four expedited drug development and review programs, including qualifying criteria, features and benefits, timelines and other considerations for sponsors.
The chart was adapted by “The Pink Sheet” from FDA’s May 2014 final guidance, “Expedited Programs for Serious Conditions – Drugs and Biologics” (see related story,([A#00140609002]).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?